Genomic Health, Inc.

Nsabp Foundation, Inc.

Bristol-myers Squibb Compnay

Nsabp Foundations, Inc.

Drew Watson

Joffre B Baker

Soonmyung Paik

Wayne Cowens

James Hackett

Kim Clark

Steven Shak

Kim Langone

Tara Maddala

Xitong Li

Lawrence Lee

Shirin K Ford

Kim Clark-Langane

David J Mauro

Kim Clark-Langone

Algorithm-based molecular assays that involve measurement of expression levels of prognostic and/or predictive genes, or co-expressed genes thereof, from a biological sample obtained from a cancer patient, and analysis of the measured expression levels to provide information concerning the likelihood of recurrence of colorectal cancer and/or the likelihood of a beneficial response to chemotherapy for the patient are provided herein. Methods of analysis of gene expression values of prognostic and/or predictive genes, as well as methods of identifying gene expression-tumor region ratios, tumor-associated stromal surface area, and gene cliques, i.e. genes that co-express with a validated biomarker and thus may be substituted for that biomarker in an assay, are also provided.

Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy

The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.

Gene expression markers for prediction of patient response to chemotherapy

A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene expression markers for colorectal cancer prognosis

The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.

Predictors of patient response to treatment with EGF receptor inhibitors

Growing community of inventors

Los Altos, CA, United States of America

Drew Watson